Screening for an ivermectin slow-release formulation suitable for malaria vector control

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Chaccour, Carlos ^a,b,c   Barrio, Ángel Irigoyen ^c   Royo, Ana Gloria Gil ^c   Urbistondo, Diego Martinez ^a   Slater, Hannah ^d   Hammann, Felix ^e   Del Pozo, Jose Luis ^a,c  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e Kantonsspital Liestal   (Switzerland)

Author keywords

Anopheles gambiae; Ivermectin; Malaria; Malaria elimination; Outdoor transmission; Residual transmission; Silicone; Slow release; Vector control

Indexed keywords

DEOXYCHOLIC ACID; IVERMECTIN; SILICONE; SUCROSE; DELAYED RELEASE FORMULATION; DRUG IMPLANT; INSECTICIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOPHELES GAMBIAE; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL MEMBRANE; COMPOSITE MATERIAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG HALF LIFE; DRUG IMPLANT; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; INSECTICIDAL ACTIVITY; MALARIA; MALARIA CONTROL; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MEMBRANE COMPONENT; NONHUMAN; PARASITE CLEARANCE; PREDICTIVE VALUE; RABBIT MODEL; RISK REDUCTION; SLOW RELEASE FORMULATION; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; VECTOR CONTROL; ADMINISTRATION AND DOSAGE; ANIMAL; DELAYED RELEASE FORMULATION; DRUG EFFECTS; INSECT VECTOR; PHARMACOKINETICS; PHARMACOLOGY; RABBIT; TOXICITY; TRANSMISSION;

ANIMALS; ANOPHELES GAMBIAE; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; INSECT VECTORS; INSECTICIDES; IVERMECTIN; MALARIA; MALE; RABBITS;

EID: 84928746002     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0618-2     Document Type: Article

References (51)

1. WHO. World Malaria report 2014. Geneva: World Health Organization; 2014.
2. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet. 2014;383:723-35.
3. Magill A. We can achieve a world free of malaria. In Impatient Optimists. Bill & Melinda Gates Foundation. 2014. http://www.impatientoptimists.org/Posts/2014/04/We-Can-Achieve-a-World-Free-of-Malaria. Accessed 17 Feb 2015
4. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011;8:e1000406.
5. Moonen B, Cohen JM, Snow RW, Slutsker L, Drakeley C, Smith DL, et al. Operational strategies to achieve and maintain malaria elimination. Lancet. 2010;376:1592-603.
6. Macdonald G. The epidemiology and control of malaria. London: Oxford University Press; 1957.
7. WHO. Global plan for insecticide resistance management in malaria vectors (GPIRM). Geneva: World Health Organization; 2012.
8. Najera JA, Gonzalez-Silva M, Alonso PL. Some lessons for the future from the Global Malaria Eradication Programme (1955-1969). PLoS Med. 2011;8:e1000412.
9. The malERA Consultative Group on Vector Control. A research agenda for malaria eradication: vector control. PLoS Med. 2011;8:e1000401.
10. Govella NJ, Ferguson H. Why use of interventions targeting outdoor biting mosquitoes will be necessary to achieve malaria elimination. Front Physiol. 2012;3:199.
11. Stevenson J, St Laurent B, Lobo NF, Cooke MK, Kahindi SC, Oriango RM, et al. Novel vectors of malaria parasites in the western highlands of Kenya. Emerg Infect Dis. 2012;18:1547-9.
12. Moiroux N, Gomez MB, Pennetier C, Elanga E, Djenontin A, Chandre F, et al. Changes in Anopheles funestus biting behavior following universal coverage of long-lasting insecticidal nets in Benin. J Infect Dis. 2012;206:1622-9.
13. Sougoufara S, Diedhiou SM, Doucoure S, Diagne N, Sembene PM, Harry M, et al. Biting by Anopheles funestus in broad daylight after use of long-lasting insecticidal nets: a new challenge to malaria elimination. Malar J. 2014;13:125.
14. Ferguson HM, Dornhaus A, Beeche A, Borgemeister C, Gottlieb M, Mulla MS, et al. Ecology: a prerequisite for malaria elimination and eradication. PLoS Med. 2010;7:e1000303.
15. Time to contain artemisinin resistance [editorial]. Lancet. 2014;383:1438.
16. WHO. Emergency response to artemisinin resistance in the Greater Mekong subregion: regional framework for action 2013-2015. Geneva: World Health organization; 2013.
17. Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Dondorp AM, et al. The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J. 2009;8:31.
18. White NJ. Artemisinin resistance-the clock is ticking. Lancet. 2010;376:2051-2.
19. Kolaczinski J, Macdonald M, Meek S. Vector control to eliminate artemisinin resistant malaria in the Greater Mekong subregion. Lancet Infect Dis. 2014;14:9-11.
20. Hii J, Rueda LM. Malaria vectors in the Greater Mekong Subregion: overview of malaria vectors and remaining challenges. Southeast Asian J Trop Med Public Health. 2013;44 Suppl 1:73-165. discussion 306-167.
21. Chaccour C, Lines J, Whitty CJ. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis. 2010;202:113-6.
22. Kobylinski KC, Deus KM, Butters MP, Hongyu T, Gray M, da Silva IM, et al. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors. Acta Trop. 2010;116:119-26.
23. Sylla M, Kobylinski KC, Gray M, Chapman PL, Sarr MD, Rasgon JL, et al. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malar J. 2010;9:365.
24. Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg. 2011;85:3-5.
25. Chaccour CJ, Kobylinski KC, Bassat Q, Bousema T, Drakeley C, Alonso P, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J. 2013;12:153.
26. Foy BD, Kobylinski KC, da Silva IM, Rasgon JL, Sylla M. Endectocides for malaria control. Trends Parasitol. 2011;27:423-8.
27. Omura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30:445-55.
28. Kobylinski KC, Foy BD, Richardson JH. Ivermectin inhibits the sporogony of Plasmodium falciparum in Anopheles gambiae. Malar J. 2012;11:381.
29. Slater HC, Walker PG, Bousema T, Okell LC, Ghani AC. The potential impact of adding Ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J Infect Dis. 2014;210:1972-80.
30. Ouedraogo AL, Bastiaens GJ, Tiono AB, Guelbeogo WM, Kobylinski KC, Ouedraogo A, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis. 2015;60:357-65.
31. Elkassaby MH. Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus. Trop Med Parasitol. 1991;42:79-81.
32. Gonzalez Canga A, Sahagun Prieto AM, Diez Liebana MJ, Fernandez Martinez N, Sierra Vega M, Garcia Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans-a mini-review. AAPS J. 2008;10:42-6.
33. Lo PK, Fink DW, Williams JB, Blodinger J. Pharmacokinetic studies of ivermectin: effects of formulation. Vet Res Commun. 1985;9:251-68.
34. Cunningham CP, Brown JM, Jacobson GA, Brandon MR, Martinod SR. Evaluation of a covered-rod silicone implant containing ivermectin for long-term prevention of heartworm infection in dogs. Am J Vet Res. 2006;67:1564-9.
35. Maeda H, Brandon M, Sano A. Design of controlled-release formulation for ivermectin using silicone. Int J Pharm. 2003;261:9-19.
36. Members of the Caucus on New and Underused Reproductive Health Technologies. Contraceptive implants. Available in the PATH website http://www.path.org/publications/files/RHSC-implants-br.pdf, 2012. Accessed 17 Feb 2015.
37. Hubacher D, Olawo A, Manduku C, Kiarie J. Factors associated with uptake of subdermal contraceptive implants in a young Kenyan population. Contraception. 2011;84:413-7.
38. Muchangi J. More Nairobi women prefer implants. In The Star newspaper. Nairobi, Kenya. 2013.
39. Trailovic SM, Nedeljkovic JT. Central and peripheral neurotoxic effects of ivermectin in rats. J Vet Med Sci. 2011;73:591-9.
40. Eraslan G, Kanbur M, Liman BC, Cam Y, Karabacak M, Altinordulu S. Comparative pharmacokinetics of some injectable preparations containing ivermectin in dogs. Food Chem Toxicol. 2010;48:2181-5.
41. Scott EW, McKellar QA. The distribution and some pharmacokinetic parameters of ivermectin in pigs. Vet Res Commun. 1992;16:139-46.
42. EMA. Guideline on bioanalytical method validation. London: European Medicines Agency; 2011.
43. Manning PJ. The biology of the laboratory rabbit. 2nd ed. 2014.
44. Griffin JT, Ferguson NM, Ghani AC. Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa. Nat Commun. 2014;5:3136.
45. Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents. 2008;31:91-8.
46. Speare R, Durrheim D. Mass treatment with ivermectin: an underutilized public health strategy. Bull World Health Organ. 2004;82:562.
47. Chavasse DC, Post RJ, Lemoh PA, Whitworth JA. The effect of repeated doses of ivermectin on adult female Onchocerca volvulus in Sierra Leone. Trop Med Parasitol. 1992;43:256-62.
48. Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50:407-10.
49. Kobylinski KCP, Alongkot UR, Schuster A, McCardle W, Foy BD, Tarning J, et al. Assessing ivermectin susceptibility of Greater Mekong Subregion malaria vectors. Poster session Annual meeting of the American Society of Tropical Medicine and Hygiene; 2014 Nov 2-6; New Orleans.
50. Deus KM, Saavedra-Rodriguez K, Butters MP, Black WCT, Foy BD. The effect of ivermectin in seven strains of Aedes aegypti (Diptera: Culicidae) including a genetically diverse laboratory strain and three permethrin resistant strains. J Med Entomol. 2012;49:356-63.
51. WHO. Malaria transmission blocking vaccines: An ideal public good. Geneva: World Health Organization; 2000.